炒股就看金麒麟分析师研报开yun体育网，巨擘，专科，实时，全面，助您挖掘后劲主题契机！

Swipe Left For English News

1

除名PSCI原则，共促价值链的可握续和负包袱发展

2

凭借构建可握续供应链的超卓指点力赢得奖项招供

3

引颈绿色生物药发展，技艺立异赋能健康将来

上海,

2025年1月15日

群众当先的合同权衡、开垦和分娩（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）告示，公司已肃肃加入“制药供应链倡议组织（PSCI）”，成为其供应商结合股伴。这一举措体现了公司对诚信运营、超卓质地和可靠性的坚忍愉快，并彰显了其勤奋于推动构建负包袱供应链践诺的决心。

PSCI 是群众制药和医疗健康限度的当先协会，其中枢就业是联袂结合股伴推动负包袱价值链构建，结束安全、环境和社会效益方面的超卓进展。药明生物在谈德、劳工与东谈主权、健康与安全、环境和管束体系等维度给与PSCI所倡导的负包袱供应链原则，更将PSCI原则深度融入供应链管束体系，积极联袂群众供应链伙伴鼓舞并实实行业最好践诺，旨在为行业带来平庸而深入的积极影响。

陈智胜

博士

药明生物首席执行官

ESG委员会主席

包容、负包袱且极具韧性的供应链是咱们业务制胜将来的要害。咱们很兴隆成为PSCI的一员，共同倡导在价值链上推行并践行负包袱的交易举止。预计将来，咱们将握续追求凸起的环境、社会和治理（ESG）进展，并赋能群众结合股伴，推动其迈向ESG发展新高度。

]article_adlist-->

近期，药明生物在2024年香港ESG求教大奖中荣获“可握续供应链指点力奖”。公司勤奋于和相似信守高谈德尺度的结合股伴共同优化交易践诺，运行行业发展。为践行这一愉快，公司制定了可握续供应链政策，设定了明确蓄意，并推断闪耀道路，如期开展除名PSCI原则的审计，为供应链伙伴提供专科培训课程，同期积极探索智商汲引容貌。这些前瞻性举措将引颈公司稳步构建愈加透明、高谈德尺度且负包袱的供应链体系。

2024年，药明生物凭借当先的绿色生物药处罚决策（Green CRDMO），告捷入选聚合国群众公约组织（UNGC）“‘二十年二十佳’企业可握续发展案例”求教。此外，公司贯串两年赢得明晟（MSCI）最高AAA ESG评级；贯串两年入选谈琼斯可握续发展指数（DJSI）；赢得国外巨擘企业可握续发展评估机构EcoVadis“铂金”奖牌；获评晨星Sustainalytics“行业最高评级”和“区域（亚太）最高评级”企业；置身CDP水安全“A级榜单”并赢得CDP形式变化指点力级别评分A-；入选富时社会包袱指数系列；入选恒生ESG 50指数，充分彰显了公司在可握续发展限度的超卓进展。

]article_adlist-->

]article_adlist-->

对于药明生物

药明生物（股票代码：2269.HK）是一家群众当先的合同权衡、开垦和分娩（CRDMO）公司。公司通过敞开式、一体化生物制药智商和技艺赋能平台，提供全办法的端到端服务，匡助结合股伴发现、开垦及分娩生物药，结束从意见到交易化分娩的全经过，加快群众生物药研发程度，裁减研发资本，造福病患。

药明生物在中国、好意思国、爱尔兰、德国和新加坡领有逾越12000名职工。通过药明生物的专科服务团队，以及先进技艺和深通洞见，公司为客户提供高效经济的生物药处罚决策。放胆2024年6月底，药明生物匡助客户研发和分娩的抽象容貌高达742个，其中包括16个交易化分娩容貌（不包括新冠容貌和非活跃容貌）。

药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的病笃组成部分，并勤奋于成为群众生物药CRDMO限度的ESG指点者，举例摆布更绿色环保的新一代生物制药技艺和动力等引颈行业发展。公司竖立了由首席执行官指点的ESG委员会，全面落实ESG政策并践行可握续性发展愉快。更多信息，请走访：www.wuxibiologics.com。

]article_adlist-->

ESG        

esg@wuxibiologics.com

媒体干系  

PR@wuxibiologics.com

WuXi Biologics Commits to PSCI and Receives Award for Sustainable Supply Chain Leadership

1

Committed to PSCI principles to promote a responsible supply chain 

2

Recognized for sustainable supply chain leadership 

3

As a leading Green CRDMO, driven by innovation for a healthier future 

Shanghai,

January 15, 2025

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner, demonstrating its strong commitment to integrity, quality, reliability, and the advancement of responsible supply chain practices.

PSCI is the leading association for pharmaceutical and healthcare companies with a common vision of excellence in safety, environmental, and social outcomes across the global healthcare value chain. WuXi Biologics fully upholds PSCI principles for responsible supply chain practices in the areas of Ethics, Human Rights and Labor, Health and Safety, Environment, and Management Systems. The company embeds PSCI principles into its own supply chain management system, actively engaging and collaborating with global suppliers to drive best practices and generate positive impacts.

Dr. Chris Chen

Chief Executive Officer

Chairman of the ESG Committee

WuXi Biologics

An inclusive, responsible, and resilient supply chain is key to our long-term business success, and we are pleased to join PSCI in advocating for responsible practices throughout the value chain. We will continuously deliver our own ESG excellence and enable our partners worldwide to fulfill their ESG commitments.

WuXi Biologics was recognized by the 2024 Hong Kong ESG Reporting Awards with a Sustainable Supply Chain Leadership Award for its outstanding performance. The company strives to conduct business with partners who share the same commitment to high ethical and sustainability standards. To create a more transparent, ethical, and responsible supply chain, WuXi Biologics formulates sustainable supply chain policies, sets tangible targets, develops refined roadmaps, performs regular PSCI audits, provides training courses, and explores capacity-building programs.

In 2024, WuXi Biologics was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions. The company was granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional ESG Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.

]article_adlist-->

About 

WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and  non-COVID dormant CMO projects).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Contacts

ESG

esg@wuxibiologics.com

Media

PR@wuxibiologics.com

]article_adlist-->

注：本信息不组成药明生物的信息泄露或投资提议

]article_adlist--> 海量资讯、精确解读，尽在新浪财经APP